Epoprostenol in Pulmonary Embolism
|ClinicalTrials.gov Identifier: NCT01014156|
Recruitment Status : Completed
First Posted : November 16, 2009
Last Update Posted : November 16, 2009
You are admitted to hospital because of pulmonary embolism. You are treated with anticoagulants.
The investigators know that, despite this treatment, pulmonary embolism can be a threat especially if heart function is compromized.
The investigators investigate a well known study drug (epoprostenol) on top of regular treatment with anticoagulants, to see if heart function can be optimized
|Condition or disease||Intervention/treatment||Phase|
|Acute Pulmonary Embolism||Drug: epoprostenol||Phase 4|
Pulmonary thromboembolism (PE) with circulatory and/or respiratory symptoms is associated with high morbidity and mortality. Acute pulmonary hypertension is the hallmark of severe PE, and is to be held responsible for the full spectrum of clinical manifestations and complications. Although it is common belief that only mechanical obstruction by thrombus mass causes this pulmonary hypertension, there is strong evidence indicating that pulmonary vasoconstriction contributes significantly to the rise in pulmonary vascular resistance.
Although all patients will receive anticoagulant treatment immediately after the diagnosis is established, morbidity and mortality are still disturbingly high when circulatory and/or respiratory symptoms accompany PE, or when hemodynamically stable PE patients have echocardiographic signs of acute right ventricle overload. There are no generally accepted guidelines for additional treatment options in these patients with moderate-to-severe PE. Thrombolytic therapy is recommended by many when hemodynamic symptoms are severe, but its effectiveness has never been proven in a controlled trial. In patients with moderate-to-large PE associated with echocardiographic signs of right ventricle overload, but who are still circulatory stable, mortality is increased, but thrombolytic therapy appears not to be beneficial.
Given the plausible role of pulmonary vasoconstriction in the pathogenesis of PE associated pulmonary hypertension, the potential benefit of pulmonary vasodilators is important.There is experimental evidence that antagonising pulmonary vasoconstriction by the administration of selective vasodilators may be beneficial in animals with PE. In addition, anecdotal evidence of a similar kind exists for humans with acute PE.
We hypothesise that in PE patients who have echocardiographic evidence of acute right ventricle overload, epoprostenol sodium (Flolan®) results in partial or complete reversal of echocardiographic abnormalities, as well as in improvement in respiratory and circulatory symptoms and signs.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism|
|Study Start Date :||January 2004|
|Actual Primary Completion Date :||June 2006|
|Actual Study Completion Date :||June 2006|
Experimental: epoprostenol intraveneously
epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
titration up to 4 ng/kg/min
Other Name: prostacyclin, flolan
- Right ventricular end diastolic diameter (ultrasound) [ Time Frame: 0, 2,5 4, 24 and 72 hours ]
- systolic pulmonary artery pressure (ultrasound) [ Time Frame: identical to primary measure ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01014156
|Free University Medical Center|
|Amsterdam, Netherlands, 1081 HV|